動脈瘤性くも膜下出血・関節リウマチ・新規診断SLEに急性虚血性梗塞を合併した症例における分子状水素投与とTr1細胞・Breg細胞・Tc細胞上TIM3発現を含む免疫マーカーの変化
A 44-year-old woman presented with aneurysmal subarachnoid hemorrhage (SAH) concurrent with rheumatoid arthritis (RA), newly identified systemic lupus erythematosus (SLE), and acute ischemic infarction. Despite multiple interventions—aneurysm embolization, immunosuppressants, non-vitamin K antagonist oral anticoagulants (NOAC), and plasmapheresis—persistent loss of consciousness was observed. Daily administration of hydrogen capsules was subsequently initiated. Following this, increases in Treg and Breg cell populations were noted, TIM3+ expression on cytotoxic T cells rose, and anti-dsDNA antibody status converted from positive to negative. Clinical stabilization occurred without documented adverse effects. This case suggests that molecular hydrogen may influence immune regulatory pathways in complex autoimmune and cerebrovascular conditions, and the authors call for further investigation.
Molecular hydrogen administration was associated with expansion of Treg and Breg cell populations and upregulation of TIM3 expression on cytotoxic T cells, suggesting modulation of immune regulatory networks and contributing to anti-dsDNA antibody negativity.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/39477420